

# TGF- $\beta$ 1 Induced Deficiency of Linc00261 Promotes Epithelial-mesenchymal-transition and Stemness of Hepatocellular Carcinoma via Modulating SMAD3

**Zhanjun Chen**

Southern Medical University

**Leyang Xiang**

Southern Medical University

**Huohui Ou**

Southern Medical University

**Yinghao Fang**

Southern Medical University

**Yuyan Xu**

Southern Medical University

**Qin Liu**

Southern Medical University

**Zhigang Hu**

Southern Medical University

**Longhai Li**

Southern Medical University

**Yu Huang**

Southern Medical University

**Xianghong Li**

Southern Medical University

**Dinghua Yang** (✉ [yangdinghua@smu.edu.cn](mailto:yangdinghua@smu.edu.cn))

Southern Medical University

---

## Research Article

**Keywords:** HCC, Linc00261, EMT, stemness, TGF- $\beta$ 1, SMAD3

**Posted Date:** November 2nd, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-986336/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Journal of Translational Medicine on February 5th, 2022. See the published version at <https://doi.org/10.1186/s12967-022-03276-z>.

# Abstract

Emerging evidence suggests that long non-coding RNAs (lncRNAs) play important roles in the metastasis and recurrence of hepatocellular carcinoma (HCC). Kinds of lncRNAs were found to be involved in regulating epithelial-mesenchymal transition (EMT) or stem-like traits in human cancers, however, the molecular mechanism and signaling pathways targeting EMT and stemness remains largely unknown. Previously, we found that linc00261 was down-regulated in HCC and associated with multiple worse clinic pathological parameters and poor prognosis. Here, we show that linc00261 was down-regulated in TGF- $\beta$ 1 stimulated cells, and forced expression of linc00261 attenuated EMT and stem-like traits in HCC. Linc00261 also inhibited the tumor sphere forming *in vitro* and decreased the tumorigenicity *in vivo*. Furthermore, we revealed that linc00261 suppressed the expression and phosphorylation of SMAD3 (p-SMAD3), which is a core transcriptional modulator in TGF- $\beta$ 1 signaling mediated EMT and the acquisition of stemness traits. A negative correlation between linc00261 and p-SMAD3 was determined in HCC samples.

**Conclusion:** Our study revealed that linc00261 suppressed EMT and stem-like traits of HCC cells by inhibiting TGF- $\beta$ 1/SMAD3 signaling.

## 1. Introduction

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and fourth leading cause of cancer-associated death worldwide[1]. Liver transplantation, surgical resection, and local radiofrequency ablation are the main curative treatments for early staging HCC, however, the early recurrence and metastasis of HCC still make the post-operative survival unsatisfactory[2]; furthermore, the vast majority of newly diagnosed patients are always with intra- or extra- hepatic metastasis. Therefore, it is urgent to illuminating the underlying mechanisms of HCC metastasis.

It has been widely accepted that epithelial-mesenchymal transition(EMT) devoted to tumor metastasis and recurrence[3–5]. Epithelial cancer cells lose epithelial characteristics and gain the mesenchymal properties during EMT. EMT-related transcriptional factors (TFs), such as Snail/Slug, ZEB1/2, TWIST1, and signaling pathways, for instance, TGF- $\beta$ /SMAD, Wnt, VEGF, IGF, and Notch are crucial triggers and regulators for EMT[6]. Cancer stem cells (CSCs), a subgroup cancer cells with self-renewal and proliferative properties, were recently thought to be the seeds of tumor metastasis and recurrence[7]. By undergoing EMT, cancer cells could acquire the “stemness”, which establishes a close relationship between EMT, CSCs, and metastasis [8].

Liver CSCs have been reported to be enriched by several surface markers, including CD13, CD133, CD24, EpCAM, CD44 and CD90[9–12]. However, the exact mechanism that liver CSCs maintain self-renewal characteristics has been rarely reported. Interestingly, pathways, such as TGF- $\beta$  pathway, Wnt/ $\beta$ -catenin pathway, Notch pathway and Hedgehog pathway, and EMT-related TFs are increasingly shown to regulate the CSCs characteristics[13–15]. TGF- $\beta$  signaling plays a dual role during the progression of HCC, it

prevents the progression of HCC in the early stage, while promoting carcinogenesis in the late stage[16]. In HCC, TGF- $\beta$  induced a partial EMT to maintain stemness characteristics, during which liver cancer cells acquire increased mobility and invasiveness[17]. However, the exact mechanism that TGF- $\beta$  signaling regulates EMT and stemness needs further investigation.

Accumulating evidences indicated that long non-coding RNAs (lncRNAs) play a significant role in regulating EMT process in cancer cells[18]. Linc00261, also known as DEANR1, has been found dysregulated in numerous cancers, such as lung cancer [19], gastric cancer[20], endometrial cancer[21], and HCC [22]. Its downregulation could be associated with transcriptional inhibition by neighbor gene FOXA2, DNMT1-derived CpG islands methylation, and EZH2 catalyzed trimethylation of H3K27 at lys27 (H3K27Me3)[23]. It inhibits cellular proliferation by promoting apoptosis, DNA damage, or G2/M cell cycle arrest, restrains cellular mobility and invasion by restricting the activation of Notch signaling[24] or accelerating the degradation of Slug[25]. Interestingly, as an endoderm differentiation specific lincRNA, linc00261 also specifically expressed in adult endoderm-derived tissues and liver shares the highest level; besides, our previous study and others revealed an inhibitory effect of linc00261 on EMT process and metastasis in HCC and gastric cancer. However, whether linc00261 deficiency modulated EMT induced acquisition of stemness, is still undefined.

In this study, we investigated the influence of linc00261 on regulating EMT and cancer stem cell-like characteristics in HCC, and the exact role of linc00261 in modulating SMAD3, the key factor of TGF- $\beta$ 1 signaling. These findings may provide new strategies for the prevention and therapy for HCC metastasis.

## 2. Materials And Methods

### 2.1. Cell lines

Liver cancer cell lines SMMC-7721 and Huh7 were bought from the Institutes of Biological Sciences, Chinese Academy of Sciences, Shanghai, China. HepG2 and Sk-Hep-1 were purchased from American Type Culture Collection (ATCC; VA, USA). and MHCC-LM3 was obtained from Liver Cancer Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China as a gift. Cell lines were cultured in DMEM (Gibco) with 10% fetal bovine serum (FBS; Gibco) at 37°C in a humidified incubator with 5% CO<sub>2</sub>. Cells were treated with TGF- $\beta$ 1 (5ng/ml) to induce the EMT.

### 2.2. RNA isolation and quantitative real-time PCR (qRT-PCR)

Total RNA was isolated using Trizol reagent RNAisoPlus (Takara, Dalian, China) and reversely transcribed into cDNA using Primescript RT Master Mix (Takara), after which, expression of target gene was evaluated by qRT-PCR using SYBR Green Mix (Takara) according to the manufacturer's instructions. The primers used were listed as follow: linc00261: 5'-GTCAGAAGGAAAGGCCGTGA-3' (forward), 5'-TGAGCCGAGATGAACAGGTG-3' (reverse); Nanog: 5'-TGAACCTCAGCTACAAACAG-3' (forward), 5'-TGGTGGTAGGAAGAGTAAAG-3' (reverse); SOX2: 5'-ACGCTCATGAAGAAGGATAAGT-3' (forward), 5'-GAGCTGGTCATGGAGTTGTAC-3' (reverse); OCT4: 5'-AGGTGGTCCGAGTGTGGTTC-3' (forward), 5'-

GAGGAGTACAGTGCAGTGAAGTG-3'(reverse);Slug:5'-CTGTGACAAGGAATATGTGAGC-3'(forward),5'-CTAATGTGTCCTTGAAGCAACC-3'(reverse);Snail:5'-CTTCCAGCAGCCCTACGAC-3'(forward),5'-CGGTGGGGTTGAGGATCT-3'(reverse);ZEB1:5'-AGCAGTGAAAGAGAAGGGAATGC-3'(forward),5'-GGTCCTCCTCAGGTGCCTCAG-3'(reverse);18SrRNA,5'-GTAACCCGTTGAACCCATT-3'(forward),5'-CCATCCAATCGGTAGTAGCG-3'(reverse). 18S rRNA was used as internal control, and  $2^{-\Delta\Delta CT}$  method was applied to analyze expression of target genes.

## 2.3. Small interfering RNA (siRNA) transfection and the construction of linc00261 overexpression cell lines

Liver cancer cell lines were seeded in the 6-well plates. Then the cells were washed three times with PBS and transfected with siRNA using lipofectamine 3000(Invitrogen), and incubated for 48hours.The siRNA sequences for linc00261 were as follow: si-linc00261-1:5'-GAAAGCTGTAGCCATTCAA-3',si-linc00261-2:5'-GCAATTAATTCAGGACACT-3'.The linc00261 overexpression lentivirus was constructed and bought from Genechem (Shanghai, China), and the construction of SMMC-7721-linc00261 overexpression model has been introduced in our previous research[23].

## 2.4. Western blotting

RIRP lysis buffer (Beyotime, Shanghai, China) containing protein inhibitor, Phenylmethanesulfonyl fluoride (Beyotime), and the BCA kit (Beyotime) was used to determine the protein concentration after collecting the supernatant. The lysed proteins were separated on an SDS-PAGE gel and transferred to a PVDF membrane for immunoblotting analysis. The membranes were immersed in TBST solution containing 5% nonfat milk at room temperature for half an hour,incubated with the primary antibodies(Table2) overnight at 4°C, and incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary IgG antibody at room temperature for 1 h. Finally, the the expression of proteins were detected using ECL substrate kit (Fdbio Science, Hangzhou, China)andFluorChem E system (ProteinSimple, CA, USA).

## 2.5. Transwell migration and invasion assays

Cells were suspended in medium without FBS and a total of  $1 \times 10^5$  cells were then added to the upper chamber. For invasion assay, the chambers were pre-coated with Matrigel (BD Biosciences).Medium supplemented with 20% FBS was added to the lower chamber. Cells were cultured at 37°C for another 48 h, after which, the invaded cells were fixed with 4% paraformaldehyde and stained using 0.5% crystal violet (Boster Biological Technology, Wuhan, China) at room temperature for 30 min. After washing with PBS, the chambers were air-dried and observed under an inverted light microscope (Olympus, Tokyo, Japan).

## 2.6. Tumor-Sphere Culture

The tumor-sphere system mainly consisted of serum-free DMEM /F12 supplemented with 10  $\mu$ L/mL B27 (Gibco)), 20ng/mL of epidermal growth factor (EGF), 10ng/mL of basic fibroblast growth factor (bFGF).

Five hundred cell were seeded in a non-adherent 6-well plates (Corning) and maintained for 2 weeks. The non-adherent spheroid clusters were observed under an inverted microscope(Olympus).

## **2.7. Immunofluorescence staining**

HCC cells seeded on coverslips were washed 3 times with PBS, fixed with 4% paraformaldehyde for 15 min, and permeabilized with 0.3% Triton X-100 at room temperature for 40 min for nuclear proteins. Then, the cells were blocked with 5% BSA for 30 min and stained with primary antibodies (Table 2) overnight at 4°C (Supplementary Table 1). After washing with PBS and incubation with Alexa fluor 594-conjugated goat-antirabbit secondary antibody (Proteintech) at dark room for 1 hour, the cells were incubated with 0.1% 4',6-diamidino-2-phenylindole (DAPI) for 5 min, washed with PBS, and then observed under an inverted fluorescence confocal microscope (Olympus).

## **2.8. Immunohistochemistry (IHC) analysis**

After deparaffinization, the tissue sections (3µm) were immersed in 10mM citrate buffer (pH 6.0) and subjected to microwave treatment for 15 min for antigen retrieval. The samples were subsequently immersed in 3% H<sub>2</sub>O<sub>2</sub> for 30 min to block endogenous peroxidase, and then incubated with primary antibodies (Table 2) at 4°C overnight. The next day, the sections were incubated with horseradish peroxidase-conjugated goat-antirabbit secondary antibody (ZSGB-BIO, Beijing, China), and developed with peroxidase substrate diaminobenzidine (DAB; ZSGB-BIO). Finally, the expression of proteins was observed and evaluated semi-quantitatively under an upright microscope (Olympus) as we previously reported.

Table 2  
Primary antibodies and its dilutions used for western blotting, immunohistochemical, immunofluorescence staining

Primary antibodies	WB	IHC-P	IF	Specificity	catalog number	Incorporation
E-cadherin	1:1000	1:300		Rabbit monoclonal	3195	Cell signaling Technology
Vimentin	1:1000	1:200		Rabbit monoclonal	5741	Cell signaling Technology
ZEB1	1:1000	1:300		Rabbit monoclonal	70512	Cell signaling Technology
Slug	1:1000		1:50	Rabbit monoclonal	9585	Cell signaling Technology
CD133	1:1000	-	-	Rabbit monoclonal	64326	Cell signaling Technology
SOX2	1:1000	1:300	1:50	Rabbit polyclonal	14962	Cell signaling Technology
SMAD3	1:1000	1:100	-	Rabbit polyclonal	ab28379	Abcam
p-SMAD3	1:1000	1:50	1:50	Rabbit monoclonal	9520	Cell signaling Technology
Oct4	1:1000	1:200	1:200	Rabbit monoclonal	2750	Cell signaling Technology
ACTB	1:1000	-	-	Rabbit polyclonal	20536-1-AP	Proteintech

## 2.9. Patients Specimens

HCC tissues and corresponding adjacent non-tumorous (NT) tissues were collected from Nanfang Hospital, Southern medical university between November 2010 and November 2016 in Nanfang Hospital. In paired HCC tissues, the relative linc00261 expression were analyzed by qRT-PCR, and IHC staining of E-cadherin, CD44, CD133, SMAD3 and p-SMAD3 was conducted.

## 2.10. In vivo Tumorigenicity

The animal experimental procedures were conducted strictly in accordance with the Guide for the Care and Use of Laboratory Animals. Male NSG mice(2-4weeks) were bought from Biocytogen(BeiJing, China).A total of 5×10<sup>6</sup>SMMC-7721 cells transfected with linc00261 overexpression or Vector lentivirus were subcutaneously implanted in the same mouse at different side. Tumor growth was recorded every 3days, and the mice were sacrificed at the 18th day after injection.

## 2.11. Statistical Analysis

The statistical significance was determined by Student's test(unpaired) or one-way ANOVA followed by a post hoc test when appropriate. Data were expressed as mean±SD, and P value of 0.05 or less was considered significant. IBM SPSS 20.0 or GraphPad prism 5 software was used for the statistical analysis.

## 3. Results

### 3.1. Linc00261 is down-regulated in TGF-β1-induced EMT in HCC cell lines

TGF-β1 is a key cytokine in the initiation of EMT and the acquisition of CSCs traits in cancers. Our previous study reported that down-regulation of linc00261 in HCC associated with poor prognosis, and participated in EMT process [22]. Thus, we explored the correlation between linc00261, TGF-β1 and TGF-β1-induced EMT and CSCs in HCC cells. After TGF-β1(5ng/mL) treatment for 48 hours, a fibroblast-like appearance was observed (Fig. 1A), and the linc00261 expression was significant down-regulated in Huh7 and HepG2 cells (Fig. 1B).Meanwhile, linc00261 was found significantly down-regulated at the early time of TGF-β1 stimulation (Fig. 1C), with the expression of Vimentin,ZEB1 upregulated, and E-cadherin expression downregulated in Huh7 cells. Besides, the expression of CSCs-relative markers, including CD133,OCT4 and SOX2, were increased which were reported to be associated with poor prognosis of HCC[26].Besides, the expression and phosphorylation of SMAD3 were also increased after TGF-β1 stimulation (Fig. 1D). Then we treated the HCC cells with SB431542,a specific inhibitor of the TGF-β signaling, the results showed that TGF-β1-induced down-regulation of linc00261 can be attenuated(Fig. 1E). These results indicated that linc00261 is a TGF-β1-induced lncRNA and may be a target of TGF-β1 pathway.

### 3.2. Linc00261 attenuated EMT and associated with stem-like traits in HCC cells

To investigate the function of linc00261 in HCC, we constructed linc00261 stably overexpression and transient knockdown models in 4liver cancer cell lines(SMMC-7721 and Sk-hep1 for overexpression, Huh7 and MHCC-LM3 for transient knockdown; Fig. 2A).After linc00261 overexpression,the expression of epithelial maker, E-cadherin was upregulated, while the expression of mesenchymal maker (Vimentin) and EMT-associated TFs (ZEB1 and Slug) were decreased; and the transient knockdown models showed the opposite trends in Huh7 and MHCC-LM3 cell lines (Fig. 2B); moreover, the linc00261 overexpression cells acquired an epithelial-like appearance comparing to the control cells(Fig. 2C).Given that linc00261 could attenuate EMT in HCC, we next examined the influence of linc00261 on the stem-like traits in HCC cells. As expected, the western blotting analysis and immunofluorescence staining revealed that linc00261 over-expression inhibited the protein levels of CSCs markers (CD44 and CD133)and CSC-TFs (SOX2and OCT4)in SMMC-7721(Fig. 3A).Conversely, the opposite changes of those proteins after linc00261



knockdown were observed in Huh7 and MHCC-LM3 cells (Fig. 3B and 3C). Further, linc00261 significantly inhibited the sphere formation in SMMC-7721 cells (Fig. 3D).

In vivo, a subcutaneous xenograft tumor formation assay was conducted using SMMC-7721 linc00261 overexpression models (Fig. 4A and B). Overexpression of linc00261 significantly reduced the tumor weights and volumes (Fig. 4C), and the IHC staining in xenograft tumors indicated that both the changes of expression of EMT-related (E-cadherin, Vimentin, Slug and ZEB1) and CSCs-related proteins (CD44, CD133, OCT4 and SOX2) were in accordance with in vitro assays (Fig. 4D and E). Taken these together, our findings strongly suggest that linc00261 attenuates EMT and is associated with stem-like traits in HCC cells.

### **3.3. Linc00261 reverses TGF- $\beta$ 1 induced EMT and inhibits TGF- $\beta$ 1-stimulated target genes expression**

Previous results have demonstrated that TGF- $\beta$ 1 plays an important role in regulating EMT and CSCs traits in hepatocellular carcinoma heterogeneity and progression [27]. To determine whether linc00261 regulate cellular migration, invasion and EMT by influencing TGF- $\beta$ 1 pathway in HCC cells, we treated linc00261 overexpression cells with TGF- $\beta$ 1. Overexpression of linc00261 abolished the migration and invasion-promoting effects of TGF- $\beta$ 1 (Fig. 5A), and remained the cells at epithelial-clone like appearance (Fig. 5B). The western blots also showed that TGF- $\beta$ 1 significantly elevated the expression of ZEB1 and Slug, however, linc00261 attenuated TGF- $\beta$ 1 induced upregulation of them; and the changes of E-cadherin were adjective with ZEB1 and Slug (Fig. 5C).

To study the role of linc00261 in TGF- $\beta$ 1 pathway, we further investigated whether linc00261 had an influence on the downstream targets of TGF- $\beta$ 1 pathway, including the key TFs of CSCs (Nanog, OCT4 and SOX2) and EMT process (Snail, Slug and ZEB1). Surprisingly, Overexpression of linc00261 significantly inhibited the mRNA expression of the downstream genes of the TGF- $\beta$ 1 signaling in SMMC-7721 cell line (Fig. 5D), and knockdown of linc00261 activated them in Huh7 cell line (Fig. 5D). The changes of these TFs in mRNA levels in xenograft tumors were in accordance with in vitro SMMC-7721 cell line (Fig. 5E). In addition, knockdown of linc00261 significantly upregulate the downstream genes in mRNA levels of the TGF- $\beta$  pathway in Huh7 and MHCC-LM3 (only Slug, Snail, and ZEB1) cells, and the activated TGF- $\beta$  signaling was blocked by ALK inhibitor, SB431542 (Figure 5F), which indicated that linc00261 has a suppressive role in TGF- $\beta$  pathway.

### **3.4. Linc00261 blocks TGF- $\beta$ signaling via inhibiting SMAD3 expression and phosphorylation.**

Our previous study revealed a direct combination of linc00261 with SMAD3 protein, which helps to guide SMAD3 protein to the promoter region of FOXA2 genome, one of the pioneer TFs in liver specification and central modulators of the sexual dimorphism of HCC [23]. In human endoderm differentiation, linc00261 also recruits SMAD2/3 to the FOXA2 promoter, thereby activating FOXA2 expression [28]. However, the exact interaction between linc00261 and SMAD3 has not been fully elucidated. We measured the total

levels of SMAD3 and its phosphorylation (*p*-SMAD3) in HCC cells after knocking down or over-expressing of linc00261. The total protein level of SMAD3, and the *p*-SMAD3 were reduced in linc00261 overexpression cells, whereas increased in linc00261 knocked-down cells (Fig. 6A and 6B). After treatment with CHX (10ng/ml) for 0, 3, and 6 hours, the SMAD3 protein was observed decreasing in Lv-linc00261 cells comparing to vector cells, however, the SMAD3 protein was increasing after treatment with MG-132 (5ng/ml) for 0, 12, and 24 hours in Lv-linc00261 cells (Fig. 6C), which indicated that linc00261 facilitates SMAD3 degradation by ubiquitin-proteasome pathway. Moreover, linc00261 could reduce TGF- $\beta$ 1-induced upregulation of total SMAD3 and *p*-SMAD3 (Fig. 6D and E); and IHC staining using the in xenograft tumors further revealed that the SMAD3 protein in both cytoplasm and nucleus, *p*-SMAD3 in nucleus were obviously decreased in Lv-linc00261 groups (Fig. 6F). These results indicated that linc00261 suppresses both SMAD3 and *p*-SMAD3 expression partially through ubiquitin-proteasome pathway.

### **3.5. Clinical relation of linc00261 with *p*-SMAD3 expression in human HCC tissues**

To further validate the correlation between linc00261 and *p*-SMAD3 expression, we tested the expressions of *p*-SMAD3 by immunohistochemical (IHC) analysis and linc00261 expression by qRT-PCR in tissues from the same cohort of HCC patients (n = 35). The *p*-SMAD3 was expressed at high levels in tumor tissues compared to non-tumor regions (Fig. 7A and B). Survival analysis showed that higher *p*-SMAD3 expression or lower linc00261 expression indicated poor RFS in HCC patients (Fig. 7C and D). Further, there was a negative correlation between linc00261 and *p*-SMAD3 protein levels (Fig. 7E). Taken together, our results indicated that linc00261 attenuated EMT and stem-like traits by facilitating SMAD3 degradation and SMAD3 phosphorylation in HCC.

## **4. Discussion**

TGF- $\beta$ 1 had been reported to be a key factor associated with the tumor EMT and stemness, leading to tumor metastasis [29, 30]. In this study, we identified that linc00261 was down-regulated after TGF- $\beta$ 1 treatment, and linc00261 attenuated EMT and stem-like traits in liver cancer cells. Mechanistically, linc00261 facilitates SMAD3 degradation through ubiquitin-proteasome pathway and SMAD3 phosphorylation, thereby inhibiting HCC metastasis.

It's well known that LncRNAs function as tumor suppressors or promoters through regulating EMT and CSCs by targeting multiple signaling pathways, including TGF- $\beta$  pathway [31]. It was reported that LncRNA H19 participated in TGF- $\beta$  signaling to regulated hepatocarcinogenesis [13]. The function of linc00261 has been investigated in multiple cancers, it suppressed lung and gastric cancer progression and metastasis by attenuated EMT [25, 32], and function as a tumor suppressor in various of human cancers by sponging with miRNA or affecting pathways [33–35]. In contrast, Gao et al. found that linc00261 was at high expression in cholangiocarcinoma, and its higher expression predicted a poorer prognosis [36]. Our previous study had demonstrated that patients with low expression of linc00261 had a poor progression in HCC, and cells after linc00261 knockdown had increased migratory and invasive

capabilities[22]; moreover, our another study revealed that linc00261 suppresses the formation of microvascular invasion, EMT, and metastasis of HCC through transcriptional upregulation of FOXA2 by recruiting SMAD3 to the FOXA2 promotor regions[23]. LncRNAs can act as cis or trans to regulate genes expression in a precise temporal and spatial manners [37]. Considering the close relation of linc00261 with SMAD3, and the observed effect of linc00261 on EMT and CSCs traits, we further investigated whether linc00261 was involved in TGF- $\beta$ 1-regulated progression of HCC.

Interestingly, we observed that linc00261 was significantly down-regulated after treatment with TGF- $\beta$ 1, which is consistent with TGF- $\beta$ 1 induced-suppression of linc00261/Foxa2 in lung cancer cells[19].According to our findings, overexpression of linc00261 induced an epithelial-like appearance, inhibited the tumor spheres formation, and also abolished TGF- $\beta$ -induced EMT, migration, and invasion in SMMC-7721; moreover, both linc00261 knockdown and overexpression affect the mRNA and protein expressions of the EMT-TFs (Slug and ZEB1) and CSCs-TFs (OCT4 and SOX2), the core downstream targets of TGF- $\beta$  pathway, besides, the activated TGF- $\beta$  signaling after linc00261 knockdown was blocked by ALK inhibitor, SB431542. All these results demonstrated that linc00261 down-regulation is necessary for TGF- $\beta$ -induced EMT, and even CSCs traits acquisition.

TGF- $\beta$ /Smad signaling has a dual role among the tumorigenicity depending on cellular context and tumor stages [38, 39]. The functions of SMAD3 in HCC were still controversial; some reports showed that it was a tumor suppressor, while others proposed that it was a tumor promoter. A recent study had demonstrated that SMAD3 could promote migration, invasion, and metastasis of HCC cells in vitro and in vivo, binding directly to PTPR $\epsilon$  promoters to activate its expression, and then feedback to activate TGF- $\beta$ /SMAD3 signaling to promote HCC metastasis[40]. Our previous study indicated that linc00261 guides SMAD3 protein to the promoter region of FOXA2 genome to enhance its transcription, thereafter contributes to the prevention of HCC progression[23]. However, whether linc00261 affect the expression and phosphorylation of SMAD3 is unknown. Herein, we found that linc00261 decreases TGF- $\beta$ 1-induced upregulation of SMAD3 and p-SMAD3; furthermore, linc00261 promotes the degradation of SMAD3 by ubiquitin-proteasome pathway and inhibits the phosphorylation of SMAD3 in vitro and in vivo. Our present findings demonstrated that linc00261 also inhibits TGF- $\beta$ /SMAD3 signaling to prevent the progression of HCC.

Our results demonstrated that TGF- $\beta$ 1-induced deficiency of linc00261 facilitates EMT and stemness via inhibiting SMAD3 in HCC. It is the first study to reveal the inhibitory role of linc00261 on TGF- $\beta$ 1/SMAD3 signaling, providing a novel mechanism underlying TGF- $\beta$ 1-induced EMT and stem-like traits in HCC. Also, our work provides a new potential therapeutic target for the treatment of HCC.

## Declarations

### Ethics approval and consent to participate:

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by The National Natural Science Foundation of China (8187-2385) and were approved under protocol NFEC-

2018-004, by Southern Medical University.

**Consent for publication:**

Not applicable.

**Competing interests:**

The authors declare no conflict of interest.

**Author Contributions:**

This study was conceptualized by Chen Zhanjun, Xiang Leyang and Yang Dinghua. Experiments were performed by Chen Zhanjun, Xiang Leyang. Analysis of the data was done by Chen Zhanjun and Xiang Leyang. The manuscript was written by Chen Zhanjun and Xiang Leyang. Figure were prepared by Chen Zhanjun. All authors have read and agreed to the published version of the manuscript.

**Acknowledgments:**

The authors thank funding support from The National Natural Science Foundation of China. Thank all of the team members for helpful discussions.

## References

1. F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *CA Cancer J Clin*, 68 (2018) 394-424.
2. K. Hasegawa, N. Kokudo, M. Makuuchi, N. Izumi, T. Ichida, M. Kudo, Y. Ku, M. Sakamoto, O. Nakashima, O. Matsui, Y. Matsuyama, Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey, *Journal of hepatology*, 58 (2013) 724-729.
3. K.R. Fischer, A. Durrans, S. Lee, J. Sheng, F. Li, S.T. Wong, H. Choi, T. El Rayes, S. Ryu, J. Troeger, R.F. Schwabe, L.T. Vahdat, N.K. Altorki, V. Mittal, D. Gao, Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance, *Nature*, 527 (2015) 472-476.
4. X. Zheng, J.L. Carstens, J. Kim, M. Scheible, J. Kaye, H. Sugimoto, C.C. Wu, V.S. LeBleu, R. Kalluri, Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer, *Nature*, 527 (2015) 525-530.
5. M. Singh, N. Yelle, C. Venugopal, S.K. Singh, EMT: Mechanisms and therapeutic implications, *Pharmacology & therapeutics*, 182 (2018) 80-94.
6. T. Shibue, R.A. Weinberg, EMT, CSCs, and drug resistance: the mechanistic link and clinical implications, *Nature reviews. Clinical oncology*, 14 (2017) 611-629.

7. T. Reya, S.J. Morrison, M.F. Clarke, I.L. Weissman, Stem cells, cancer, and cancer stem cells, *Nature*, 414 (2001) 105-111.
8. A. Singh, J. Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer, *Oncogene*, 29 (2010) 4741-4751.
9. S. Ma, K.W. Chan, L. Hu, T.K. Lee, J.Y. Wo, I.O. Ng, B.J. Zheng, X.Y. Guan, Identification and characterization of tumorigenic liver cancer stem/progenitor cells, *Gastroenterology*, 132 (2007) 2542-2556.
10. M. Zoller, CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?, *Nature reviews. Cancer*, 11 (2011) 254-267.
11. Z.F. Yang, D.W. Ho, M.N. Ng, C.K. Lau, W.C. Yu, P. Ngai, P.W. Chu, C.T. Lam, R.T. Poon, S.T. Fan, Significance of CD90+ cancer stem cells in human liver cancer, *Cancer cell*, 13 (2008) 153-166.
12. T. Yamashita, J. Ji, A. Budhu, M. Forgues, W. Yang, H.Y. Wang, H. Jia, Q. Ye, L.X. Qin, E. Wauthier, L.M. Reid, H. Minato, M. Honda, S. Kaneko, Z.Y. Tang, X.W. Wang, EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features, *Gastroenterology*, 136 (2009) 1012-1024.
13. J. Zhang, C. Han, N. Ungerleider, W. Chen, K. Song, Y. Wang, H. Kwon, W. Ma, T. Wu, A novel TGF-beta and H19 signaling axis in tumor-initiating hepatocytes that regulates hepatic carcinogenesis, *Hepatology*, (2018).
14. P. Zhu, Y. Wang, G. Huang, B. Ye, B. Liu, J. Wu, Y. Du, L. He, Z. Fan, Inc-beta-Catm elicits EZH2-dependent beta-catenin stabilization and sustains liver CSC self-renewal, *Nature structural & molecular biology*, 23 (2016) 631-639.
15. N. Takebe, L. Miele, P.J. Harris, W. Jeong, H. Bando, M. Kahn, S.X. Yang, S.P. Ivy, Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update, *Nature reviews. Clinical oncology*, 12 (2015) 445-464.
16. K. Yamazaki, Y. Masugi, M. Sakamoto, Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-beta signaling in hepatocarcinogenesis, *Dig Dis*, 29 (2011) 284-288.
17. A. Malfettone, J. Soukupova, E. Bertran, E. Crosas-Molist, R. Lastra, J. Fernando, P. Koudelkova, B. Rani, A. Fabra, T. Serrano, E. Ramos, W. Mikulits, G. Giannelli, I. Fabregat, Transforming growth factor-beta-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma, *Cancer letters*, 392 (2017) 39-50.
18. M. Gugnoni, A. Ciarrocchi, Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer, *International journal of molecular sciences*, 20 (2019).
19. S. Dhamija, A.C. Becker, Y. Sharma, K. Myacheva, J. Seiler, S. Diederichs, LINC00261 and the Adjacent Gene FOXA2 Are Epithelial Markers and Are Suppressed during Lung Cancer Tumorigenesis and Progression, *Noncoding RNA*, 5 (2018).
20. Y. Fan, Y.F. Wang, H.F. Su, N. Fang, C. Zou, W.F. Li, Z.H. Fei, Decreased expression of the long noncoding RNA LINC00261 indicate poor prognosis in gastric cancer and suppress gastric cancer

- metastasis by affecting the epithelial-mesenchymal transition, *Journal of hematology & oncology*, 9 (2016) 57.
21. L. Sha, L. Huang, X. Luo, J. Bao, L. Gao, Q. Pan, M. Guo, F. Zheng, H. Wang, Long non-coding RNA LINC00261 inhibits cell growth and migration in endometriosis, *The journal of obstetrics and gynaecology research*, (2017).
  22. Z. Chen, L. Xiang, Y. Huang, Y. Fang, X. Li, D. Yang, [Expression of long noncoding RNA linc00261 in hepatocellular carcinoma and its association with postoperative outcomes], *Nan Fang Yi Ke Da Xue Xue Bao*, 38 (2018) 1179-1186.
  23. Z. Chen, L. Xiang, Z. Hu, H. Ou, X. Liu, L. Yu, W. Chen, L. Jiang, Q. Yu, Y. Fang, Y. Xu, Q. Liu, Y. Huang, X. Li, D. Yang, Epigenetically silenced linc00261 contributes to the metastasis of hepatocellular carcinoma via inducing the deficiency of FOXA2 transcription, *American journal of cancer research*, 11 (2021) 277-296.
  24. S. Shahabi, V. Kumaran, J. Castillo, Z. Cong, G. Nandagopal, D.J. Mullen, A. Alvarado, M.R. Correa, A. Saizan, R. Goel, A. Bhat, S.K. Lynch, B. Zhou, Z. Borok, C.N. Marconett, LINC00261 Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response, *Cancer research*, 79 (2019) 3050-3062.
  25. Y. Yu, L. Li, Z. Zheng, S. Chen, E. Chen, Y. Hu, Long non-coding RNA linc00261 suppresses gastric cancer progression via promoting Slug degradation, *Journal of cellular and molecular medicine*, 21 (2017) 955-967.
  26. K. Kohga, T. Tatsumi, T. Takehara, H. Tsunematsu, S. Shimizu, M. Yamamoto, A. Sasakawa, T. Miyagi, N. Hayashi, Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma, *Journal of hepatology*, 52 (2010) 872-879.
  27. F. Dituri, S. Mancarella, A. Cigliano, A. Chieti, G. Giannelli, TGF-beta as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives, *Seminars in liver disease*, 39 (2019) 53-69.
  28. W. Jiang, Y. Liu, R. Liu, K. Zhang, Y. Zhang, The lncRNA DEANR1 facilitates human endoderm differentiation by activating FOXA2 expression, *Cell reports*, 11 (2015) 137-148.
  29. H.W. Yeh, E.C. Hsu, S.S. Lee, Y.D. Lang, Y.C. Lin, C.Y. Chang, S.Y. Lee, D.L. Gu, J.H. Shih, C.M. Ho, C.F. Chen, C.T. Chen, P.H. Tu, C.F. Cheng, R.H. Chen, R.B. Yang, Y.S. Jou, PSPC1 mediates TGF-beta1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis, *Nature cell biology*, 20 (2018) 479-491.
  30. S. Rao, S. Zaidi, J. Banerjee, W. Jogunoori, R. Sebastian, B. Mishra, B.N. Nguyen, R.C. Wu, J. White, C. Deng, R. Amdur, S. Li, L. Mishra, Transforming growth factor-beta in liver cancer stem cells and regeneration, *Hepatology communications*, 1 (2017) 477-493.
  31. J.H. Yuan, F. Yang, F. Wang, J.Z. Ma, Y.J. Guo, Q.F. Tao, F. Liu, W. Pan, T.T. Wang, C.C. Zhou, S.B. Wang, Y.Z. Wang, Y. Yang, N. Yang, W.P. Zhou, G.S. Yang, S.H. Sun, A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma, *Cancer cell*, 25 (2014) 666-681.

32. J. Liao, L.P. Dong, Linc00261 suppresses growth and metastasis of non-small cell lung cancer via repressing epithelial-mesenchymal transition, *Eur Rev Med Pharmacol Sci*, 23 (2019) 3829-3837.
33. S. Zhai, Z. Xu, J. Xie, J. Zhang, X. Wang, C. Peng, H. Li, H. Chen, B. Shen, X. Deng, Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1, *Oncogene*, 40 (2021) 277-291.
34. D. Yan, W. Liu, Y. Liu, M. Luo, LINC00261 suppresses human colon cancer progression via sponging miR-324-3p and inactivating the Wnt/beta-catenin pathway, *Journal of cellular physiology*, 234 (2019) 22648-22656.
35. T. Chen, S. Lei, Z. Zeng, J. Zhang, Y. Xue, Y. Sun, J. Lan, S. Xu, D. Mao, B. Guo, Linc00261 inhibits metastasis and the WNT signaling pathway of pancreatic cancer by regulating a miR5525p/FOXO3 axis, *Oncology reports*, 43 (2020) 930-942.
36. J. Gao, W. Qin, P. Kang, Y. Xu, K. Leng, Z. Li, L. Huang, Y. Cui, X. Zhong, Up-regulated LINC00261 predicts a poor prognosis and promotes a metastasis by EMT process in cholangiocarcinoma, *Pathology, research and practice*, 216 (2020) 152733.
37. F. Kopp, J.T. Mendell, Functional Classification and Experimental Dissection of Long Noncoding RNAs, *Cell*, 172 (2018) 393-407.
38. M.A. Taylor, Y.H. Lee, W.P. Schiemann, Role of TGF-beta and the tumor microenvironment during mammary tumorigenesis, *Gene Expr*, 15 (2011) 117-132.
39. J. Seoane, R.R. Gomis, TGF-beta Family Signaling in Tumor Suppression and Cancer Progression, *Cold Spring Harb Perspect Biol*, 9 (2017).
40. Z. Liao, L. Chen, X. Zhang, H. Zhang, X. Tan, K. Dong, X. Lu, H. Zhu, Q. Liu, Z. Zhang, Z. Ding, W. Dong, P. Zhu, L. Chu, H. Liang, P.K. Datta, B. Zhang, X. Chen, PTPRepsilon Acts as a Metastatic Promoter in Hepatocellular Carcinoma by Facilitating Recruitment of SMAD3 to TGF-beta Receptor 1, *Hepatology*, (2020).


## Table

Table 1 is not available with this version.

## Supplementary Table

Supplementary Table 1 is not available with this version.


## Figures



**Figure 1**


TGF-β1 induced the down-regulation of linc00261 expression in HCC cells. (A) Morphological changes in liver cancer cells treated with TGF-β1(left). (B) Linc00261 was down-regulated after TGF-β1 treatment in HepG2,Huh7 cells determined by qRT-PCR(right). (C) Quantitative RT-PCR analysis of linc00261 expression at points in Huh 7 cells after TGF-β1 treatment. (D) Western blotting analysis of EMT, CSCs and TGF-β pathway related markers' expression after TGF-β1 treatment. (E) qRT-PCR analysis of linc00261 expression, TGF-β1 induced down-regulation of linc00261 can be attenuated by SB431542. \*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ .





**Figure 2**


Linc00261 inhibits EMT progression in HCC cells.(A) Quantitative RT-PCR analysis of linc00261 expression in HCC cells(SMMC-7721,SK-Hep1,Huh7 and MHCC-LM3) after linc00261 overexpression or linc00261 knockdown.(B) The protein expressions of epithelial(E-cadherin) and mesenchymal associated markers (Vimentin)/transcription factors(ZEB1 and Slug) determined by western blotting after linc00261 overexpression in SMMC-7721 and SK-Hep1 or linc00261 knockdown in Huh7 and SMMC-LM3. (C)Linc00261 overexpression inhibits morphological changes in SMMC-7721 and SK-Hep1. \* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001.



**Figure 3**


Linc00261 regulates CSC marker gene expression levels in HCC cells. (A) Western blotting analysis (left) and immunofluorescence microscopy analysis of CSC-markers (CD44 and CD133) and CSC-TF (SOX2 and OCT4) protein levels in SMMC-7721 cells transfected with control and linc00261-overexpression plasmids. (B,C) Western blotting analysis of CSC-markers (CD44 and CD133) and CSC-TF (SOX2 and OCT4) protein levels in Huh7 cells and MHCC-LM3 cells transfected with control siRNA or siRNA against linc00261. (D) Linc00261 overexpression inhibits sphere formation in SMMC-7721 cells. \*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$





**Figure 4**

Linc00261 inhibits the growth of HCC cells in vivo. (A) Images of xenografts show that linc00261 overexpression decrease tumor mass and volume in SMMC-7721 cells. Relative expression of linc00261 in xenografts. (C) IHC analysis of EMT-related markers(E-cadherin,Vimentin,Slug and ZEB1) between both groups. (D)IHC analysis of CSC-related markers(CD44,CD133,OCT4 andSOX2) between both groups.\* P< 0.05; \*\* P < 0.01; \*\*\* P< 0.001




**Figure 5**

Linc00261 reverses TGF- $\beta$ 1 induced EMT and inhibits TGF- $\beta$ 1-stimulated target genes expression.

(A) Transwell invasion and migration of linc00261 overexpression or control cells with or without TGF- $\beta$ 1 (5ug/ml) in SMMC-7721 cells. (B) Morphological photos of linc00261 overexpression or control cells with or without TGF- $\beta$ 1 treatment in SMMC-7721. (C) Western blotting analysis of EMT-related markers' protein levels. (D) Linc00261 overexpression inhibits while linc00261 down-regulation upregulated EMT-




TFs(Slug,Snai and ZEB1) and CSC-TFs(Nanog,OCT4 and SOX2)at the RNA levels determined by quantitative RT-qPCR analysis. (E) Linc00261 overexpression also inhibits the EMT-TFs(Slug,Snai and ZEB1) and CSC-TFs(Nanog,OCT4 and SOX2) at theRNA levels in vivo. (F) SB431542 inhibits the up-regulation of EMT-TFs(Slug,Snai and ZEB1) and CSC-TFs(Nanog,OCT4 and SOX2) after linc00261 konckdown in Huh7 and SMMC-LM3 cells.\* P< 0.05; \*\* P < 0.01; \*\*\* P< 0.001.



**Figure 6**

Linc00261 blocks TGF-β signaling via inhibiting SMAD3 expression and phosphorylation. (A,B) Western blotting analysis of SMAD3 and P-SMAD3 protein levels after linc00261 knockdown or linc00261 overexpression. (C) CHX and MG132 affect SMAD3 protein degradation in linc00261 overexpression SMMC-7721 cells.(D) Western blotting analysis of total or phospho-Smad3 protein expression in linc00261 overexpression or control cells treated with or without TGF-β1 in SMMC-7721 cells.(E) immunofluorescence staining analysis SMAD3 and P-SMAD3 protein levels after linc00261 overexpression.(F) IHC analysis SMAD3 and P-SMAD3 protein levels in vivo.



**Figure 7**

Correlation between linc00261 and p-Smad3 in patient samples. (A) IHC analysis of p-Smad3 protein expression in 35 human HCC tissues and paired normal tissues (B) RT-qPCR analysis of relative linc00261 expression in the same 35 human HCC tissues and paired normal tissues. (C) High p-Smad3 protein expression was associated with poor progression in human HCC patients. (D) Low linc00261 expression was associated with poor progression in human HCC patients. (E) Correlation of linc00261 and p-Smad3 expression in 35 human HCC tissues. (F) Schematic diagram of the inhibition of EMT and stemness of linc00261 in HCC cells. \*\*\* P < 0.001.